Extended Renal Outcomes with Use of Iodixanol versus Iohexol after Coronary Angiography

Table 1

Baseline profile and short-term impact on renal function (cohort A).

Variables	Cohort A	Iodixanol (Visipaque)	Iohexol (Omnipaque)	value
	Age, mean (SD), years	65.1 (12.1)	67.4 (12.0)		62.5 (11.8)	<0.0001
Age > 65 years, No. (%)	282 (50.4)	177 (59.6)	105 (39.9)	<0.001
Male gender, No. (%)	389 (69.5)	202 (68.0)	187 (71.1)	0.43
Comorbidities, No. (%)
Diabetes mellitus	93 (16.6)	60 (20.2)	33 (12.6)	0.02
Hypertensive heart disease	337 (60.2)	184 (62.0)	153 (58.2)	0.36
CCF	59 (10.5)	39 (13.1)	20 (7.6)	0.03
Critical illness (within 1 wk after contrast)	53 (9.5)	30 (10.1)	23 (8.8)	0.58
Baseline renal function
Serum Cr, median (IQR), μmol/L	81 (68–98)	86 (72–110)	75 (63–86)	<0.0001
eGFR*, mean (SD), mL/min/1.73 m^2	79 (28)	71 (27)	88 (26)	<0.0001
eGFR* < 60 mL/min/1.73 m^2, No. (%)	138 (24.6)	110 (37.0)	28 (10.7)	<0.001
eGFR* < 45 mL/min/1.73 m^2, No. (%)	57 (10.2)	46 (15.5)	11 (4.2)	<0.001
Primary cardiac disease, No. (%)
Suspect CAD (angina or CAD NOS)	172 (30.7)	79 (26.6)	93 (35.4)	0.03
STEMI	113 (20.2)	91 (30.6)	22 (8.4)	<0.001
NSTEMI	176 (31.4)	70 (23.6)	106 (40.3)	<0.001
Arrhythmias	26 (4.6)	12 (4.0)	14 (5.3)	0.47
Valvular heart disease/septal defects	13 (2.3)	9 (3.0)	4 (1.5)	0.27
Cardiomyopathy	17 (3.0)	11 (3.7)	6 (2.3)	0.33
Noncardiac issues	9 (1.6)	7 (2.4)	2 (0.8)	0.18
Others	34 (6.1)	18 (6.1)	16 (6.1)	0.99
Contrast load, median (IQR)
Contrast volume, mL	150 (100–230)	160 (100–240)	145 (100–210)	0.80
Iodine content, g	51 (34–77)	51 (32–77)	51 (35–74)	0.14
Iodine : eGFR ratio, g per mL/min/1.73 m^2	0.66 (0.44–1.02)	0.73 (0.47–1.13)	0.60 (0.42–0.91)	0.006
Iodine : eGFR ratio > 0.7	251 (44.8)	150 (50.5)	101 (38.4)	0.004
Procedure details, No. (%)
Coronary angiogram	551 (98.4)	291 (98.0)	260 (98.9)	0.51
PCI	278 (49.6)	163 (54.9)	115 (43.7)	0.008
Aortogram	34 (6.1)	17 (5.7)	17 (6.5)	0.71
LVgram	365 (65.2)	191 (64.3)	174 (66.2)	0.65
IABP	7 (1.3)	5 (1.7)	2 (0.8)	0.46
Renal function at 3 days after contrast
Peak sCr, median (IQR), μmol/L	87 (73–106)	96 (81–121)	78 (67–90)	<0.0001
Median day of peak sCr	1 (1-2)	1 (1-2)	1 (1-2)	0.13
ΔCr, median (IQR), μmol/L	4 (−2–16)	8 (−2–20)	1 (−3–10)	0.001
RIFLE “R/I/F”^#, No. (%)	99 (17.7)	65 (21.9)	34 (12.9)	0.006
RIFLE “I/F”^#, No. (%)	21 (3.8)	14 (4.7)	7 (2.7)	0.20

*4-variable MDRD eGFR equation; ^#RIFLE acute kidney injury classification (“R/I/F” refers to “at-risk/injury/failure” classes, respectively).
Δ: delta (change in); CAD: coronary artery disease; CCF: congestive cardiac failure; D: day; eGFR: estimated glomerular filtration rate; IABP: intra-aortic balloon pump; IQR: interquartile range; LVgram: left ventriculogram; No.: number; NOS: not otherwise specified; NSTEMI: non-ST elevation myocardial infarction; PCI: percutaneous coronary intervention; pts: patients; sCr: serum creatinine; SD: standard deviation; STEMI: ST elevation myocardial infarction; wk: week.